RapilogTM
Insulin Aspart
Analog Insulin (Antidiabetic Preparations)
Indication:
Type 1 and Type 2 Diabetes Mellitus, Gestational Diabetes Mellitus.
Dosage & Administration:
=RapilogTM has a faster onset of action, RapilogTMshould generally be given immediately before a meal. When necessary RapilogTM may be given soon after a meal. Dosage of RapilogTM is individual and determined on the basis of the physician’s advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day. The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by RapilogTM and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if
patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.
Subcutaneous Injection
RapilogTM should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because RapilogTM has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal
Intravenous Use
RapilogTM can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, RapilogTM should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. RapilogTM has been shown to be stable in infusion fluids such as 0.9% sodium chloride.
Preparation:
RapilogTM Injection: Each box contains 3 ml glass vial.
RapilogTM Pen Cartridge: Each box contains 3 ml glass Cartridge.
